Sabin Vaccine Institute and Eisai Co., Ltd. announced a memorandum of understanding (MOU) “to advance the development of vaccines to combat neglected tropical diseases (NTDs), a group of parasitic and bacterial infections that afflict more than 1.4 billion people who live on less than $1.25 a day.” Sabin and Eisai “will collaborate on research and development for NTD vaccines and help deepen the pharmaceutical industry’s role in global health initiatives for NTDs. In addition, Sabin Vaccine Development-a product development partnership of the Sabin Vaccine Institute-intends to test Eisai’s vaccine adjuvant technology in preclinical studies with antigens that are currently in development. Eisai’s adjuvant technology may serve as a valuable tool for enhancing immunogenicity of Sabin’s vaccine antigens for human hookworm infection and schistosomiasis.”

http://sabin.org/news-resources/releases/2011/04/05/sabin-vaccine-institute-and-eisai-co-ltd-announce-collaboration-a